The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The companies aim to expand treatment options for millions living with metabolic disorders
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The study met its primary endpoint and all 11 secondary efficacy endpoints
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Subscribe To Our Newsletter & Stay Updated
